Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT03543839RecruitingPhase 4
Belimumab for early lupus activity in the first two years
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
Manhasset, New YorkAges 18 years+ - NCT03549416Recruiting
BioDay Registry collects information on new eczema treatments
This registry study collects questionnaire information from people with atopic dermatitis (eczema) who are starting newer whole-body (systemic) treatments. It may help doctors better understand how these new options work in everyday care.
Nijmegen, GelderlandAges birth+ - NCT03557619RecruitingPhase 1
Venetoclax test in women with specific non-Hodgkin lymphomas
This Phase 1 study tests how venetoclax affects certain hormone pills (ethinyl estradiol and levonorgestrel) in women with different non-Hodgkin lymphomas. It’s mainly looking at safety and drug interactions, which could help guide treatment for people who need hormone-based contraception.
Detroit, MichiganAges 18 years+ - NCT03562169RecruitingPhase 3
Ixazomib with your own stem cell transplant for relapsed myeloma
This trial studies whether adding ixazomib (an oral drug) to a transplant using your own stem cells can control relapsed multiple myeloma better. It may help by strengthening anti-myeloma treatment after the transplant, aiming to delay disease progression.
AberdeenAges 18 years+ - NCT03568266Recruiting
Genetic study of liver injury from a leukemia medicine
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
Los Angeles, CaliforniaAges 18 years+ - NCT03569826Recruiting
Study for primary biliary cholangitis and autoimmune hepatitis
This study is for people diagnosed with primary biliary cholangitis or autoimmune hepatitis. It aims to learn more about these autoimmune liver conditions and may help guide better care in the future.
Calgary, AlbertaAges 18 years+ - NCT03572465Recruiting
Ultrasound tests to diagnose fatty liver inflammation
This study checks whether special ultrasound measurements can help diagnose nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. You may need a liver biopsy as part of routine care, and you may also be scanned with MRI to support the study tests.
Montreal, QuebecAges 18 years+ - NCT03587844RecruitingPhase 2
Test dosing of brentuximab for skin lymphoma
This Phase 2 study tests how brentuximab vedotin should be dosed for people with mycosis fungoides or Sezary syndrome (skin T-cell lymphoma), and also for lymphomatoid papulosis. It may help improve how well the treatment works while tracking side effects.
Stanford, CaliforniaAges 18 years+ - NCT03590171RecruitingPhase 2
Study for children with relapsed high-risk ALL
This Phase 2 study tests a treatment approach for children with high-risk ALL that has returned. It aims to improve outcomes after relapse by using a planned treatment schedule.
Clayton, VictoriaAges Up to 17 years - NCT03595917RecruitingPhase 1
New and hard-to-treat BCR-ABL leukemia drugs plus prednisone and blinatumomab
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
Chicago, IllinoisAges 18 years+ - NCT03601286RecruitingPhase 1
Gene therapy for X-linked SCID using a modified virus
This early-stage study tests a one-time lentiviral gene therapy to help children with X-linked severe combined immunodeficiency (SCID-X1) make infection-fighting T cells. It may reduce the need for a matching donor transplant, but it requires long-term follow-up for safety over many years.
London, Greater LondonAges 2 months–5 years - NCT03603977Recruiting
Simplified HIV treatment for people living with HIV
This trial looks at whether a simpler set of HIV medicines works for people with confirmed HIV-1 infection. It may help by making treatment easier to follow, while monitoring health with regular blood tests.
Guangzhou, GuangdongAges 18 years+ - NCT03615742RecruitingPhase 4
Study how diesel fumes affect asthma medicine response
This trial looks at how diesel exhaust exposure can change how well asthma “steroid” medicine works in your body. It may help researchers understand why some asthma symptoms are harder to control and guide better treatment strategies.
Vancouver, British ColumbiaAges 19–49 - NCT03616483Recruiting
Indiana Myeloma Registry for blood cancer-related diagnoses
This registry collects information from adults with certain plasma-cell conditions like MGUS, smoldering multiple myeloma, multiple myeloma, plasmacytoma, or primary amyloidosis. It may help researchers learn more about these diseases and improve future care.
Indianapolis, IndianaAges 18 years+ - NCT03621137Recruiting
Registry for people with moderate-to-severe eczema
This registry collects information about people with atopic eczema who begin light therapy (phototherapy) or medicine that changes the immune system. It may help doctors better understand how these treatments work in everyday care in the Netherlands.
Amsterdam, North HollandAges Any age - NCT03621553RecruitingPhase 4
Vitamin D balance study in people with sarcoidosis
This Phase 4 study looks at how your body keeps vitamin D levels balanced in sarcoidosis. It may help researchers understand what affects calcium and vitamin D in sarcoidosis, and guide safer care.
Dallas, TexasAges 21 years+ - NCT03633955RecruitingPhase 1
Imaging study for people with high-risk leukemia
This early (Phase 1) study tests how a special scan works in people with relapsed or hard-to-treat leukemia types. The scan uses a tracer called 18F FLT, and the study looks to see if it can be done safely (without sedation) and how it relates to treatment.
Washington D.C., District of ColumbiaAges 4–80 - NCT03643276RecruitingPhase 3
Study of treatment plans for children with leukemia
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
SydneyAges Up to 17 years - NCT03647072RecruitingPhase 3
Test drug to reduce stomach side effects during lymphoma chemotherapy
This Phase 3 trial studies whether a proton pump inhibitor (a stomach acid blocker) works better than histamine-blocking medicines when added to chemotherapy for DLBCL lymphoma. The goal is to improve how well chemotherapy is tolerated or how the treatment works.
CairoAges 18 years+ - NCT03647852Recruiting
Study for difficult IgA vasculitis with gut symptoms
This study looks at treatment strategies for children with IgA vasculitis (also called Henoch-Schönlein purpura) when it mainly affects the stomach and intestines and symptoms do not improve with standard steroid dosing. It may help find better ways to control the illness early and prevent serious complications.
ShanghaiAges 2–16 - NCT03648918Recruiting
Study family genetics in type 1 diabetes
This study looks at genetic patterns in families where someone has type 1 diabetes (an autoimmune condition). It may help researchers understand why type 1 diabetes happens and who is at risk.
Milwaukee, WisconsinAges 2 years+ - NCT03659227Recruiting
Sample collection for serious drug skin reactions
This study collects skin and blood samples from adults who have a serious rash caused by medicines. The goal is to better understand these reactions and how to diagnose them sooner and more accurately.
CréteilAges 18 years+ - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Gilbert, ArizonaAges 18 years+ - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.